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Glomerulosclerosis in mice transgenic for human insulin-like cluding collagen types I, III, and IV, laminin, fibronectin,
growth factor-binding protein-1. and various proteoglycans [2–4]. They result from com-
Background. The growth hormone (GH)/insulin-like growth plex interactions between cells, growth factors, and extra-
factor (IGF) system is thought to participate in the glomerulo-
cellular matrix [1]. In particular growth hormone (GH)/sclerosis process. Because IGF-binding proteins (IGFBPs)
insulin-like growth factor I (IGF-I) system is thought tomodulate IGF actions and hence GH secretion, this study as-
sessed whether mice transgenic for human IGFBP-1 have al- play a specific role in the development of glomeruloscle-
tered susceptibility to glomerulosclerosis. rosis. Mice transgenic for bovine GH (bGH) have high
Methods. A line of transgenic mice that express human circulating GH levels, display a giant phenotype, and
IGFBP-1 mRNA in the liver under the control of the a1-antitryp-
develop glomerular hypertrophy and progressive glo-sin promoter has been obtained, and morphological changes
merulosclerosis leading to end-stage renal failure andin the kidney tissue were assessed. Glomerulosclerosis was
identified using light microscopy, light microscopic morphome- death within eight to nine months of age [5–8]. Con-
try, and electron microscopy. Extracellular matrix components versely, mice transgenic for a mutated form of GH, which
were analyzed by immunohistochemistry. acts as an antagonist of endogenous GH, display a dwarf
Results. There was a marked increase in mesangial extracel-
phenotype and not only develop no glomerulosclerosis,lular matrix area in homozygous transgenic mice at three months
but also fail to develop glomerular hypertrophy or le-of age as compared with heterozygous transgenic mice and
nontransgenic littermates. These changes were not associated sions on streptozotocin (STZ)-induced diabetes [9–12].
with alterations in glomerular volume or cellularity. The expan- Whereas most of the effects of GH are mediated by
sion of extracellular matrix area was related to a marked in- IGF-I [13], evidence has arisen that circulating IGF-I
crease in laminin and type IV collagen and to the appearance
may not be involved in the induction of glomerulosclero-of type I collagen.
sis. Indeed, glomerular hypertrophy occurs in mice trans-Conclusions. These observations indicate that the enhanced
genic for IGF-I as in mice transgenic for GH, but noexpression of IGFBP-1 may result in the development of glo-
merulosclerosis without glomerular hypertrophy. The changes glomerulosclerosis is found in mice transgenic for IGF-I,
are potentially related to a decrease in IGF-I availability and/or even though circulating levels of IGF-I are greater in
to an IGF-I-independent role of IGFBP-1. these mice than in mice transgenic for GH [6].
In addition to GH and IGF-I, the GH/IGF-I system
comprises IGF-binding proteins (IGFBPs). IGFBP-1 to
Progressive glomerular sclerosis is the principal fea- -6 play a key role in regulating IGF-I bioavailability
ture of several forms of glomerular diseases leading to in the circulation and the extracellular space [14]. By
chronic renal failure [1]. The lesions are characterized reducing IGF-I bioavailability in pituitary, IGFBPs po-
by an increase in the mesangial matrix components, in- tentially limit the negative feedback normally exerted
by circulating IGF-I on GH secretion [15] and, hence,
may worsen GH-dependent glomerulosclerosis. By mod-Key words: growth hormone, insulin-like growth factor, glomerular
ifying IGF-I bioavailability in renal tissue, IGFBPs mayextracellular matrix, progressive glomerulosclerosis, chronic renal
failure. directly contribute to the development of glomeruloscle-
rosis, as observed in experimental diabetes [14]. Thus,Received for publication May 6, 1999
the importance of the GH/IGF-I system in the glomeru-and in revised form November 11, 1999
Accepted for publication January 17, 2000 losclerosis process might be further assessed in modifying
the expression of IGFBPs.Ó 2000 by the International Society of Nephrology
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This study was designed to characterize the suscepti- rial surface area [18]. Using Adobe Photoshop 4.0
(Adobe Systems Inc., San Jose, CA, USA) in conjunctionbility to glomerulosclerosis of mice transgenic for human
IGFBP-1 [16]. In these mice, the transgene is placed under with NIH Image 1.61, both the total glomerular area
(including nuclei and spaces within capillary loops) andthe control of a liver-specific promoter, and the permanent
(though moderate) elevation of plasma IGFBP-1 levels mesangial area (excluding nuclei and area of capillary
loops) were determined, and the relative mesangial arearesults in reduced IGF-I bioavailability [16]. We exam-
ined kidney sections from such IGFBP-1 transgenic mice was expressed as a percentage of the total glomerular
area to assess the severity of glomerulosclerosis [20].using standard histology, morphometry, and immunohis-
tochemistry techniques and compared them with those The nuclei in 50 successive glomerular profiles were
counted by scanning PAS-stained tissue sections usingof nontransgenic littermates. The results indicate that
despite the restricted availability of IGF-I, these trans- serpentine movements, and the relative glomerular cell
number was calculated [21].genic mice develop progressive glomerulosclerosis.
Immunohistochemistry. Kidney sections were evalu-
ated immunohistochemically for their expression of ex-METHODS
tracellular matrix proteins using the Envisione horse-
Animals radish peroxidase System (Dako Corp., Carpinteria, CA,
Transgenic B6/CBA mice carrying the human a1-anti- USA). Briefly, tissues previously fixed in 2.5% PFA were
trypsin promoter fused to human IGFBP-1 complemen- suspended in 0.15 mol/L NaCl containing 30% sucrose
tary DNA have been described elsewhere [16]. The pro- for 24 hours, frozen in liquid nitrogen vapors, and stored
moter was selected in order to obtain a liver-specific at 2808C. Four micrometer sections were cut and
expression of the transgene. Heterozygous and homozy- mounted on saline-coated glass slides. The slides were
gous transgenic animals and nontransgenic littermates dried, fixed in acetone for 10 minutes at 48C, dried for
were identified on the basis of Southern blot analysis of 30 minutes at room temperature, and either stored at
DNA samples from tail biopsies [16]. 2208C or directly postfixed in 4% PFA for 20 minutes
Experimental parameters were compared in female at 48C. Thereafter, the slides were washed and incubated
homozygous and heterozygous transgenic mice, nontrans- at room temperature in PBS containing 3% bovine se-
genic littermates, and wild-type B6/CBA mice (N 5 5 rum albumin (BSA), 10% normal goat serum, and puri-
for each group). Animals were sacrificed at three months fied rabbit anti-m type IV collagen Ig (6.4 mg/mL; Rock-
of age. Urine and blood samples were collected before land, Gilbertville, PA, USA), anti-m type I collagen Ig
sacrifice. The mice were anesthetized with sodium pento- (1 mg/mL; Rockland), and anti-m laminin Ig (0.2 mg/mL;
barbital (0.6 mg/10 g body weight intraperitoneally), and Chemicon, Temecula, CA, USA) diluted to 1:400, 1:400,
blood was drawn from the aorta in ethylenediaminetetra- and 1:200, respectively. After one hour, the slides were
acetic acid (EDTA) tubes for determination of GH. washed, incubated for one hour at room temperature
Plasma samples were stored at 2208C until measure- with peroxidase-labeled goat antirabbit Ig, washed again,
ments were performed. The left kidney was perfused and incubated for 15 minutes at room temperature in
through the aorta, first with 0.15 mol/L NaCl and then a 3,39-diamino-benzidine chromogen solution. Finally,
with 2.5% paraformaldehyde (PFA) in 0.15 mol/L NaCl. tissue sections were dehydrated in ethanol and counter-
Thereafter, it was removed and stored in 2.5% PFA stained with H&E, and cover slips with Eukitt Mounting
for at least 24 hours before sections were prepared for Medium (Electro Microscopy Science, Fort Washington,
examination by light microscopy, electron microscopy, PA, USA) were applied. Slides were examined without
and immunochemistry. The right kidney was removed the knowledge of the group, and the staining intensity
without prior perfusion and weighed. was graded on a 1 to 31 scale.
Electron microscopy. Electron microscopy was per-
Renal histology formed for only two homozygous transgenic mice and
Light microscopy. Blocks of fixed kidney tissue were one nontransgenic littermate at three months of age.
taken and embedded in paraffin. Two-micrometer sec- Tissues collected in 2.5% PFA were fixed in cold 2.5%
tions were routinely stained with hematoxylin and eosin glutaraldehyde/0.1 mol/L cacodylate buffer, pH 7.2, for
(H&E), periodic acid-Schiff (PAS), Masson’s trichrome, one hour, postfixed in 1% osmium tetroxide/0.1 mol/L
and silver methenamine (PASM). The kidney sections cacodylate buffer for one hour, dehydrated in acetone,
were examined without prior knowledge of the group, and embedded in epoxy resin (Epon; Polysciences Inc.,
and mesangial sclerosis was recorded using a scoring Warrington, PA, USA). Semithin sections were stained
method with a scale from 0 to 31 [17]. with toluidine blue and examined by light microscopy
to identify regions of the blocks containing several glo-Morphometry. Morphometric analyses were performed
on kidney sections using a digitizing tablet and a video meruli. Ultrathin sections were stained with uranyl ace-
tate and lead citrate and were examined with a Phillipscamera [18, 19]. The mean glomerular volume was de-
rived from the harmonic mean of the glomerular equato- EM 200 electron microscope.
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Table 1. Glomerular volume, glomerular cellularity, and relativeMeasurement of blood pressure
mesangial area
Systolic blood pressure was measured by the tail-cuff
Homozygous Heterozygousmethod adapted to the mouse [22]. Four to 12 measure- transgenic transgenic Nontransgenic
ments were performed at two-minute intervals in animals mice mice litter mates
previously accustomed for several days. Glomerular volume
310 6 lm3 0.2960.09 0.3560.08 0.4260.08
Glomerular cellPlasma analysis
number 24.464.1 24.762.6 23.563.2
Plasma creatinine and urea were measured using a Mesangial area/total
glomerular area % 20.3263.14a 13.3263.14 7.0961.19standard colorimetric method.
Each group included five mice.Plasma GH levels were measured by radioimmunoas-
aP , 0.001 vs. nontransgenic littermates and P , 0.05 vs. heterozygous trans-say, using rabbit antirat GH antibody to detect mouse genic mice
GH, as previously described [23]. This antibody has 95%
cross-reactivity with mouse growth hormone (mGH).
The limit of sensitivity of the assay was 1.635 ng/mL.
which was not associated with hypercellularity (Table 1).
Mesangial sclerosis varied in intensity between individ-Urine analysis
ual glomeruli but was regularly distributed between theSpot urine samples were used for determination of
cortical and juxtamedullary regions. There was no in-creatinine and protein, using the Jaffe´ method and the
crease in the thickness of the glomerular basement mem-Bradford assay (Bio-Rad, Hercules, CA, USA), respec-
branes. Completely obsolescent glomeruli, crescents,tively. The protein (mg/dL)/creatinine (mg/dL) ratio was
and synechiae were not observed.calculated.
In contrast, there was no evidence of glomerulosclero-
sis in heterozygous transgenic mice of the same age.Statistical analysis
However, at eight months, these mice presented diffuse
All results are given as mean values 6 SD. Differences glomerulosclerosis that was as severe as that in homozy-
between multiple groups were analyzed by one-way anal- gous transgenic mice at three months.
ysis of variance in combination with Tukey’s multiple Using a semiquantitative scoring method, the mean
comparison test. The independent chi-square test was mesangial sclerosis was 2.87 6 0.25, 1.87 6 0.85, and
used for comparisons of the proportions of undetectable 1.20 6 0.27 in homozygous transgenic, heterozygous
GH levels in the plasma of the three groups of mice. A transgenic, and nontransgenic mice, respectively. Using
P value of , 0.05 was considered significant. a quantitative analysis of the relative mesangial area,
there was a statistically significant increase in the mesan-
gial area/total glomerular area ratio in homozygousRESULTS
transgenic mice as compared with either heterozygousBody weight, kidney weight, and glomerular volume
transgenic mice (P , 0.05) or nontransgenic littermates
At three months of age, the homozygous transgenic (P , 0.001; Table 1). Moreover, some glomerular lesions
mice had significantly lower body weights as compared were associated with increased amounts of PAS-positive
with the heterozygous transgenic mice and nontransgenic material in the vascular pole (Fig. 2). Such deposits were
littermates (18.3 6 0.4 g vs. 22.8 6 1.8 g and 22.8 6 1.9 g, more frequent in homozygous and heterozygous trans-
respectively, P , 0.01). Such growth retardation is in genic mice than in nontransgenic littermates (28.5 6 12.6
agreement with our earlier findings for a large series of and 34.7 6 10.4 vs. 8.53 6 4.47%, respectively; P , 0.05).
animals [16]. Similarly, kidney weights were significantly Finally, there were no tubulointerstitial lesions and only
lower in homozygous transgenic mice than in heterozy- few vascular sclerotic lesions in either homozygous or
gous transgenic mice or nontransgenic littermates (0.14 6 heterozygous mice.
0.02 g vs. 0.20 6 0.02 g and 0.19 6 0.03 g, respectively, Immunohistochemistry. The semiquantitative scoring
P , 0.05). Consequently, the kidney weight/body weight method revealed larger amounts of laminin and type IV
ratio did not differ significantly between the three groups collagen and the appearance of type I collagen in the
of mice. The glomerular volume was similar in the three mesangial area of three-month-old homozygous trans-
groups of mice (Table 1). genic mice (Table 2 and Fig. 3). These findings were
consistent with the increase in extracellular mesangial
Renal histology matrix evidenced by light microscopy. In contrast, there
Light microscopy. At three months of age, all of the were no such increases in laminin or type IV collagen
homozygous transgenic mice had severe and diffuse glo- and no expression of type I collagen in the mesangial
merular lesions (Fig. 1). Glomeruli exhibited an in- area of heterozygous transgenic mice or nontransgenic
littermates of the same age.creased amount of mesangial PAS-positive material,
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Fig. 1. Light micrographs of a glomerulus from homozygous transgenic mice (A), heterozygous transgenic mice (B), and nontransgenic mice (C).
All mice were three months old (PAS stain, final magnification 3400).
Table 2. Quantitation of mesangial matrix accumulation
by immunohistochemistry
Homozygous Heterozygous
transgenic transgenic Nontransgenic
mice mice littermates
Laminin 1.9260.47a 1.1060.23 1.2060.14
Type IV collagen 1.7860.49b 1.2060.05 1.0560.01
Type I collagen 1.3560.20b 1.0960.11 1.0060.00
Each group included five mice.
aP , 0.01 vs. heterozygous transgenic mice
bP , 0.05 vs. heterozygous transgenic mice and nontransgenic littermates
Electron microscopy. The homozygous transgenic
mice at three months had larger amounts of mesangial
matrix, but these were not associated with a thickening
of the peripheral basement membrane (Fig. 4). Podo-
cytes and endothelium appeared normal.
Blood pressure
There were no significant differences in the mean sys-
tolic blood pressure between homozygous transgenic
mice and nontransgenic littermates (84.8 6 9.3 mm Hg,
N 5 3, and 82.7 6 7.6 mm Hg, N 5 4, respectively).
Urine protein/creatinine ratios
There were no significant differences in the mean uri-
nary protein/creatinine ratios between homozygous trans-
genic mice, heterozygous transgenic mice, and nontrans-
genic littermates at three months (Table 3). However,
at eight months of age, the homozygous transgenic mice
Fig. 2. Light micrographs of a glomerulus from homozygous transgenic had significantly higher urinary protein/creatinine ratios
mice (A) and nontransgenic mice (B). All mice were three months old. as compared with the heterozygous transgenic mice andPAS-positive materials in the vascular pole are indicated by an arrow.
Magnification is 3400. nontransgenic littermates (Table 3).
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Fig. 3. Immunochemistry micrographs of a glomerulus stained by mAb that was reactive with laminin (first column), type IV collagen (second
column), or type I collagen (third column). (A, B, and C) Homozygous transgenic mice. (D, E, and F ) Nontransgenic mice. All mice were three
months old. Magnification is 3400.
Plasma creatinine and urea levels zygous transgenic mice, and nontransgenic littermates,
respectively (Fig. 5). Detectable GH levels ranged fromThere were no significant differences in mean plasma
2 to 10 ng/mL in the three groups of mice, with thecreatinine levels between homozygous transgenic mice
exception of a higher value (22 ng/mL) in one homozy-(N 5 9) and nontransgenic littermates (N 5 14) at eight
gous transgenic mouse.months (35.4 6 7.4 and 36.3 6 5.6 mmol/L, respectively).
Although homozygous transgenic mice displayed tend-
encies toward increase in plasma urea levels as compared DISCUSSION
with nontransgenic littermates at eight months (11.03 6 To determine the importance of IGFBP-1 in the devel-
3.93 and 9.17 6 1.81 mmol/L, respectively), these changes opment of glomerulosclerosis, we used a model of trans-
were not statistically significant. genic mice producing human IGFBP-1 under the control
of a liver-specific promoter [16]. In these mice, plasma
Plasma GH levels levels of IGFBP-1, which directly reflect transgene ex-
The hormone was not detectable in plasma from 69.2, pression, are only moderately elevated even in homozy-
gous mice (13.7 6 1.4 ng/mL as compared with 3.0 685.7, and 76.6% of homozygous transgenic mice, hetero-
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Fig. 4. Electron microscopic photograph of a glomerulus from homozygous transgenic mice (A) and nontransgenic mice (B). All mice were three
months old (314,000).
Table 3. Urine protein/creatinine ratios
Age in Homozygous Heterozygous Nontransgenic
months mice mice mice
3 0.6260.23 (4) 0.4360.03 (17) 0.5660.08 (7)
8 1.9161.16a (3) 0.5760.19 (10) 0.4260.10 (5)
The number of mice is indicated in parentheses.
aP , 0.05 vs. heterozygous transgenic mice and nontransgenic littermates
0.4 ng/mL in heterozygous mice) [16]. Nevertheless,
these mice (particularly the homozygous) exhibit sig-
nificant postnatal growth retardation [16]. This growth
deficiency is attributable to a decrease in IGF-I bioavail-
ability that results from both an excess of IGFBP-1 and
a lack of IGF-I. Indeed, plasma IGF-I concentrations Fig. 5. Plasma concentrations of GH in homozygous transgenic mice,
heterozygous transgenic mice, and nontransgenic mice of three monthsare decreased by half in homozygous adult transgenic
of age. The baseline indicates the limit of sensitivity of the assay.mice as compared with nontransgenic littermates [16].
Our results show that homozygous and heterozygous
IGFBP-1 transgenic mice develop glomerulosclerosis
that is evident at three and eight months of age, respec- gial matrix, that is, collagen types I and IV, laminin, and
heparan sulfate proteoglycan [5, 6]. However, in thosetively. Extracellular matrix components such as collagen
types I and IV and laminin accumulate in the mesangium, animals, glomeruli become disproportionately enlarged
as compared with either kidney weight or body weight,but there is no evidence of glomerular hypertrophy or
hypercellularity. Such lesions have been previously de- and the number of glomerular cells was increased. Renal
changes in experimental diabetes include both short- andscribed in association with other changes in the GH/
IGF system. In transgenic mice overexpressing bGH or long-term changes [14]. Although at the early stages of
the disease glomerular hypertrophy takes place, at laterhuman GH-releasing factor (hGHRF), glomerular le-
sions include similar increases in the proteins of mesan- stages, extracellular matrix accumulates in the mesan-
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gium. At that time, alterations in GH-IGF axis are simi- der the curve for glycemia (unpublished data). On the
basis of the close association between glomerulosclerosislar in diabetic animals and IGFBP-1 transgenic mice. In
particular, the IGF-I level is reduced, while IGFBP-1 and hyperglycemia/hypercholesterolemia under a vari-
ety of experimental conditions [1], it is tempting to sug-availability is increased. In contrast with these animals,
transgenic mice overexpressing human IGF-I develop gest that such metabolic changes may participate in the
development of glomerulosclerosis in IGFBP-1 trans-glomerular hypertrophy without glomerulosclerosis [6].
The glomerular volume is increased but to a lesser extent genic mice. Nevertheless, because these changes are
moderate, their contribution is probably limited.than that found in bGH or hGHRF transgenic mice.
There is no increase in the amount of mesangial collagen Numerous studies describing the hepatic secretion of
IGFBP-1 and the nyctemeral variations of plasma IGFBP-1type IV, laminin, and heparan sulfate proteoglycan, and
there is no appearance of collagen type I in the glomeruli. levels in relationship to feeding and fasting indicate that
plasma IGFBP-1, by crossing the capillary boundary,Thus, the study of both IGFBP-1 transgenic mice (glo-
merulosclerosis without glomerular hypertrophy) and controls the bioavailability of free IGF in the tissues.
When IGFBP-1 plasma levels are high, as is consistentlyIGF-I transgenic mice (glomerular hypertrophy without
glomerulosclerosis) would confirm previous studies that seen in malnutrition, IGF bioavailability is reduced [28].
As a consequence, strong IGFBP-1 expression from thedemonstrate that glomerulosclerosis and glomerular hy-
pertrophy are independent events [24]. fetal period is associated with intrauterine growth retar-
dation in animal models and in humans [29, 30]. InRenal lesions in both heterozygous and homozygous
IGFBP-1 transgenic mice at three months of age also IGFBP-1 transgenic mice, excessive IGFBP-1 produc-
tion from the fetal period is responsible for growth retar-include injuries of the glomerular vascular pole and the
arterioles that are not seen in diabetic animals or GH- dation, heavy neonatal mortality [16], and flaws in renal
development. Indeed, we have noted a 20% reductionor GHRF-overexpressing mice. In bGH transgenic mice,
arterial and/or arteriolar lesions are not present before in nephron number in adult transgenic mice (manuscript
in preparation). Such a preliminary result is consistent9 to 10 months of age, when only minimal focal thick-
ening is noted in the intima of arterioles [5]. with recent studies showing that the number of nephrons
per kidney is reduced by approximately 20% in miceThe mechanisms by which glomerular lesions are gen-
erated in IGFBP-1 transgenic mice appear to be due to with an inactive IGF-I gene [31]. As a decrease in the
number of nephrons at birth is implicated in the patho-IGFBP-1 overexpression. The role of IGFBP-1 is further
suggested by the correlation between IGFBP-1 levels genesis of glomerulosclerosis [32], this reduction may
account for the development of glomerulosclerosis le-and the severity of glomerular lesions that are more
severe in homozygous than in heterozygous mice. First sions in IGFBP-1 mice. However, the development of
glomerulosclerosis in response to nephron reduction de-IGFBP-1 overexpression might induce glomerulosclero-
sis by promoting GH overexpression. This would result pends largely on the genetic background of the mice
[24]. Thus, further studies are needed to clarify the im-from the suppression by IGFBP-1 of the IGF-I–mediated
negative feedback on GH secretion [15]. However, our portance of this mechanism in our particular IGFBP-1
mice.results are inconsistent with this hypothesis. Measurable
plasma GH concentrations in IGFBP-1 transgenic mice Given the role of IGF-I in tissue repair and prevention
of cell apoptosis [33, 34], the reduced IGF-I bioavailabil-were not significantly different from those of controls.
Even recent assays performed on pituitary samples from ity may also lead to glomerulosclerosis through an in-
crease in cell apoptosis. Consistent with this hypothesisthese mice have shown that, far from being increased,
GH is diminished in the pituitary, particularly in homozy- are the recent findings that glomerular cell apoptosis
is involved in the pathogenesis of focal and segmentalgous mice (manuscript in preparation). This would ac-
count for the low plasma concentrations of IGF-I [16] glomerulosclerosis [35]. Finally, IGFBP-1 may have ad-
ditional direct and IGF-independent effects. Indeed, theand the absence of glomerular hypertrophy and hyper-
cellularity noted in these mice. The physiopathological RGD sequence at its carboxy-terminal extremity is capa-
ble of binding a5b1 integrin [28]. Such interactions couldmechanisms leading to glomerulosclerosis under these
conditions remain speculative. Long-term GH deficiency disturb the connections between the extracellular matrix
and the cytoskeleton that are essential for cell survivalleads to impaired glucose and lipid metabolism with high
plasma levels of glucose, insulin, triglycerides, and free [36]. For example, IGFBP-1 has been shown in vitro to
both increase the migration of Chinese hamster ovaryfatty acids [25]. In their model of IGFBP-1 transgenic
mice, Rajkumar et al noted fasting hyperglycemia, hy- cells [37] and cause the detachment of human breast
cancer cells from the extracellular matrix [38]. The latterperinsulinemia, and glucose intolerance [26, 27]. Prelimi-
nary results from glucose tolerance tests performed in event, which is associated to a dephosphorylation of local
adhesion kinase, precedes cell apoptosis.our transgenic mice also indicated an increased area un-
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